APONTIS PHARMA and Midas Pharma announce development partnership to launch Single Pill with pan-European intellectual property rights

– Continued expansion of the mid-term Single Pill portfolio for the treatment of hypertension
– APONTIS PHARMA for the first time owns all Europe-wide rights (IP-Intellectual Property) to the preparation, medication, or Single Pill

Monheim am Rhein, 14 December 2021

APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company specializing in Single Pills in the German market, continues to consistently implement its communicated growth strategy. Today the Single Pill Company announces a development partnership with the German company Midas Pharma. The objective is the contract development of a Single Pill with a combination of three leading active ingredients for the treatment of high blood pressure (hypertension). The development of this Single Pill will further strengthen APONTIS PHARMA's portfolio in the medium term.

For the first time, APONTIS PHARMA owns the EU-wide rights (IP - Intellectual Property) to the combined medication. As a result, the Company has new opportunities in terms of out-licensing for marketing and distribution beyond the borders of its home market in Germany. The Single Pill addresses a large and continuously growing group of hypertension patients. In Germany alone, around 225,000 people are currently taking a loose combination of the three active ingredient classes. By the time the product is launched on the market in 2026, the two partner companies expect around 360,000 people to use it. This corresponds to an average annual growth rate of more than ten percent.

The Single Pill therapy approach is well proven. Combining up to three active ingredients in just one tablet increases patient compliance compared to loose combinations. It is the basis for a more efficient and thus more successful therapy. Compared to conventional therapies, Single Pills sustainably reduce event rates and hospitalizations. The success of the Single Pill therapy strategy is proven by the START study conducted in 2019. As a result, patients benefit from a Single Pill versus a substance-matched Multi Pill regimen.

"The established, trusting partnership with Midas Pharma for Single Pill developments has so far exclusively covered the German market. For this reason, this new development partnership represents a milestone in APONTIS PHARMA's corporate history. For the first time, we have EU-wide property rights for the medication and can thus reach patients in additional country markets. We are pleased to have a competent and experienced partner in Midas Pharma at our side who shares our vision of a more efficient, innovation-driven therapy," says Karlheinz Gast, Chief Executive Officer (CEO) of APONTIS PHARMA AG.

"Our two companies have already been working together in a spirit of trust for many years on a whole range of new combination products. APONTIS PHARMA and Midas Pharma have an innovative and effective approach to Single Pills. As a strategic partner for global pharmaceutical projects, especially as a developer and supplier (CDMO) of products and provider of complementary services along the pharmaceutical value chain, we have developed a great deal of expertise. The two partners jointly contribute their strengths to support a dynamically growing patient group in their therapy with Single Pill products," says Karl-Heinz Schleicher, owner, and CEO of Midas Pharma.


APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two to three patent-free active ingredients in a single dosage form. APONTIS PHARMA develops, promotes,       and sells a broad portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia, and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is located in one of Europe's leading pharmaceutical and chemical regions. From here, the Company maintains a broad network with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

About Midas Pharma

Midas Pharma is a pharmaceutical company based in Ingelheim, Germany, that offers products, services and expertise along the entire pharmaceutical value chain - from Starting Materials and Active Pharmaceutical Ingredients to market ready Finished Products and Devices.

Since over three decades the family-owned company has successfully contributed to the Pharma sector and has step by step expanded its competencies. For 2021 Midas Pharma Group is expecting an annual turnover of about 400 Mio. EUR.

With more than 250 employees and 10 locations in all major pharmaceutical markets worldwide Midas Pharma has excellent local know-how, local contacts and well-established networks in different pharmaceutical sectors (biological products, small molecules and medical devices).

Thanks to many years of experience and extensive expertise, Midas Pharma has a proven track record of successfully supporting its customers in coordinating even complex pharmaceutical projects and creating significant added value.

Your Contact

Andreas Kahm

Andreas Kahm

Business Development
Senior Manager

Midas Pharma GmbH
Rheinstr. 49
55218 Ingelheim
Send E-Mail

Share this page